Rivaroxaban and Acetylsalicylic Acid for Prevention of Venous Thromboembolism Following Total Knee Arthroplasty in Korean Patients
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To investigate the incidence of venous thromboembolism (VTE) after total knee arthroplasty (TKA) with chemoprophylaxis using acetylsalicylic acid (AA) or rivaroxaban in Korean patients. Materials and Methods: Between May 2011 and November 2013, 268 TKA patients (330 cases) were randomly allocated to 3 groups (group A: subcutaneous injection of 5,000 IU lowmolecularweight heparin for 2 days followed by oral administration of 100 mg AA for 5 days; group X7: oral administration of 10mg rivaroxaban for 7 days; and group X10: oral administration of 10 mg rivaroxaban for 10 days). Multidetectorrow computed tomography (MDCT) was performed at 10 days and 3 months postoperatively to evaluate VTE changes. Results: The VTE incidence was 38.2%, 20.0%, and 10.0% in groups A, X7, and X10, respectively (p<0.001). Pulmonary embolism (PE) was identified in 19.1%, 10.0%, and 2.7% in groups A, X7, and X10, respectively (p<0.001). Proximal or symptomatic deep vein thrombosis (DVT) occurred primarily in group A, but the incidence was not significantly different among groups. On followup MDCT, PE was resolved completely with treatment in 29/30 (96.7%), and so was asymptomatic distal DVT in 24/27 (88.8%) without treatment. Conclusions: Rivaroxaban had a lower incidence of overall VTE than AA, but no difference was observed in symptomatic VTE. The 10day course of rivaroxaban had a lower incidence of overall VTE than the 7day course.
Abstract
Purpose: To investigate the incidence of venous thromboembolism (VTE) after total knee arthroplasty (TKA) with chemoprophylaxis using acetylsalicylic acid (AA) or rivaroxaban in Korean patients. Materials and Methods: Between May 2011 and November 2013, 268 TKA patients (330 cases) were randomly allocated to 3 groups (group A: subcutaneous injection of 5,000 IU lowmolecularweight heparin for 2 days followed by oral administration of 100 mg AA for 5 days; group X7: oral administration of 10mg rivaroxaban for 7 days; and group X10: oral administration of 10 mg rivaroxaban for 10 days). Multidetectorrow computed tomography (MDCT) was performed at 10 days and 3 months postoperatively to evaluate VTE changes. Results: The VTE incidence was 38.2%, 20.0%, and 10.0% in groups A, X7, and X10, respectively (p<0.001). Pulmonary embolism (PE) was identified in 19.1%, 10.0%, and 2.7% in groups A, X7, and X10, respectively (p<0.001). Proximal or symptomatic deep vein thrombosis (DVT) occurred primarily in group A, but the incidence was not significantly different among groups. On followup MDCT, PE was resolved completely with treatment in 29/30 (96.7%), and so was asymptomatic distal DVT in 24/27 (88.8%) without treatment. Conclusions: Rivaroxaban had a lower incidence of overall VTE than AA, but no difference was observed in symptomatic VTE. The 10day course of rivaroxaban had a lower incidence of overall VTE than the 7day course.
참고문헌 (26)
- Geerts WH, "Prevention of venous thromboembolism: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition)", Chest, 133(6 Suppl), pp.381S~453S (2008)[DOI]
- Lee WS, "The incidence of pulmonary embolism and deep vein thrombosis after knee arthroplasty in Asians remains low: a meta-analysis", Clin Orthop Relat Res, 471, pp.1523~1532 (2013)[DOI]
- Piovella F, "Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography", J Thromb Haemost, 3, pp.2664~2670 (2005)[DOI]
- Leizorovicz A, "Epidemiology of post-operative venous thromboembolism in Asian patients: results of the SMART venography study", Haematologica, 92, pp.1194~1200 (2007)[DOI]
- Russell RD, "The efficacy and safety of rivaroxaban for venous thromboembolism prophylaxis after total hip and total knee arthroplasty", Thrombosis, 2013, pp.762310~ (2013)
- White RH, "Effects of race and ethnicity on the incidence of venous thromboembolism", Thromb Res, 123(Suppl 4), pp.S11~S17 (2009)[DOI]
- Ryu JH, "Clinical recognition of pulmonary embolism: problem of unrecognized and asymptomatic cases", Mayo Clin Proc, 73, pp.873~879 (1998)[DOI]
- Wang CJ, "Outcome of calf deep-vein thrombosis after total knee arthroplasty", J Bone Joint Surg Br, 85, pp.841~844 (2003)
- Jaffe TA, "Radiation dose for body CT protocols: variability of scanners at one institution", AJR Am J Roentgenol, 193, pp.1141~1147 (2009)[DOI]
- Saltybaeva N, "Estimates of effective dose for CT scans of the lower extremities", Radiology, 273, pp.153~159 (2014)[DOI]
- Colwell CW Jr, "Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty", J Bone Joint Surg Am, 87, pp.2169~2177 (2005)
- Turpie AG, "Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial", Lancet, 373, pp.1673~1680 (2009)[DOI]
- Westrich GH, "Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty", J Bone Joint Surg Br, 82, pp.795~800 (2000)[DOI]
- Eriksson BI, "Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement", J Thromb Haemost, 4, pp.121~128 (2006)
- Jacobs JJ, "American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty", J Bone Joint Surg Am, 94, pp.746~747 (2012)[DOI]
- Falck-Ytter Y, "Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 141(2 Suppl), pp.e278S~e325S (2012)[DOI]
- Turpie AG, "Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial", Lancet, 359, pp.1721~1726 (2002)[DOI]
- Lieberman JR, "Prevention of venous thromboembolic disease after total hip and knee arthroplasty", J Bone Joint Surg Am, 87, pp.2097~2112 (2005)[DOI]
- 이진규, "한국인에서 슬관절 전치환술 시 정맥혈전색전증의 예방적 치료", 대한정형외과학회지, 47(2), pp.86~95 (2012), 대한정형외과학회[DOI]
- Kyung-Hyun Park, "Incidence of Venous Thromboembolism Using 64 Channel Multidetector Row Computed Tomography-Indirect Venography and Anti-Coagulation Therapy after Total Knee Arthroplasty in Korea", Knee Surgery and Related Research, 24(1), pp.19~24 (2012), 대한슬관절학회
- Byrne JJ, "Fatal pulmonary emboli; a study of 130 autopsy proven fatal emboli", Am J Surg, 83, pp.47~49 (1952)[DOI]
- Kahn SR, "The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis", J Thromb Thrombolysis, 21, pp.41~48 (2006)[DOI]
- Barrack RL, "Current guidelines for total joint VTE prophylaxis: dawn of a new day", J Bone Joint Surg Br, 94(11 Suppl A), pp.3~7 (2012)[DOI]
- Winer-Muram HT, "Suspected acute pulmonary embolism: evaluation with multi-detector row CT versus digital subtraction pulmonary arteriography", Radiology, 233, pp.806~815 (2004)[DOI]
- Park EA, "Chronic-stage deep vein thrombosis of the lower extremities: indirect CT venographic findings", J Comput Assist Tomogr, 31, pp.649~656 (2007)[DOI]
- Mettler FA Jr, "Effective doses in radiology and diagnostic nuclear medicine: a catalog", Radiology, 248, pp.254~263 (2008)[DOI]